Navigation Links
Translating Preclinical Pharmacology to Clinical Activity with Myriad RBM’s Inflammation MAP
Date:4/22/2013

Toronto, Canada (PRWEB) April 22, 2013

Pre-clinical assessment of a novel investigational product should include an evaluation of the compounds’ pharmacokinetic/pharmacodynamic (PK/PD) profile. This information, combined with toxicology studies, is crucial for deciding dosage regimens. New approaches, such as Minimal Anticipated Biological Effect Level (MABEL), can inform go/no-go decisions for additional clinical research.

In this webinar, a case study using the immunotherapeutic small molecule VTX-2337, will help to show how this preclinical evaluation can be done effectively. VTX-2337 is a potent and selective small molecule (<500 MW) TLR8 agonist that activates myeloid dendritic cells, monocytes and NK cells to produce both chemokines and Th1 polarizing cytokines, including TNFa, IL-12 and IFN?.

The presenter, Dr. Gregory Dietsch, Vice President of Research at VentiRx Pharmaceuticals, will discuss translating preclinical pharmacology to clinical activity with Myriad RBM’s Inflammation MAP.

To join the webinar and engage in an online discussion about preclinical pharmacology and VTX-2337, visit: http://xtks.in/xto594wp

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global Life Sciences community. Every year, thousands of industry practitioners turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks, visit http://xtalks.com/ContactUs.ashx.

Contact:
Karen Lim (416) 977-6555 ext 227
clientservices(at)xtalks(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10652881.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
2. RPCI-Led Study: FAK Inhibitor Proves Effective Against Brain Tumors in Preclinical Studies
3. Stemline Therapeutics, Inc. Announces Presentations of SL-401 Updated Clinical Trial Results in Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and SL-101 Preclinical Efficacy Data Against Hodgkins Lymphoma at
4. Inovio Pharmaceuticals Cytomegalovirus (CMV) Synthetic Vaccine Constructs Generate Strong and Broad T-Cell Responses in Preclinical Study
5. Karyopharm Therapeutics Announces Oral Presentation at the American College of Rheumatology (ACR) on the use of Selective Inhibitors of Nuclear Export (SINE) CRM1 Antagonists in preclinical models of Systemic Lupus Erythematosus (SLE)
6. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
7. Karyopharm Therapeutics announces the Publication of Two Preclinical Studies on the Activity of Selective Inhibitors of Nuclear Export (SINE) in Acute Myeloblastic Leukemia (AML)
8. MultiCell Technologies Announces Positive Preclinical Results for MCT-465 and MCT-485 in Primary Liver Cancer In Vitro Models
9. AtheroNova Inc. Preclinical Study Demonstrates 95% Reduction in Arterial Plaque Formation
10. ChemoCentryx Presents Positive Results for Novel CCR2 Inhibitor in Preclinical Models of Diabetic Nephropathy at the 44th Annual Meeting of the American Society of Nephrology
11. A “Fail Fast” Strategy for Lead Optimization Pharmacology and Toxicology, New Xtalks Life Sciences Webinar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
(Date:2/9/2016)... Feb. 9, 2016 ... 2016", report provides in depth insights on ... around the Protein-Tyrosine Phosphatase 1B (PTP1B) Inhibitors. ... in various stages of development including Discovery, ... III and Preregistration. Report covers the product ...
(Date:2/8/2016)...  CytRx Corporation (NASDAQ: CYTR ), a ... today announced that it has entered into a ... Growth Capital, Inc. and Hercules Technology III, L.P. ... --> --> CytRx ... under the loan and security agreement.  The proceeds ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... ... Board of Directors. Todorow is the Executive Vice President for Corporate Services and ... Todorow oversees Finance, Accounts Payable, Payroll, Billing Operations, Treasury, Managed Care Contracting, Supply ...
Breaking Biology Technology:
(Date:2/3/2016)... Feb. 3, 2016 Vigilant Solutions announces today ... in Missouri solved two recent ... (LPR) data from Vigilant Solutions. Brian Wenberg ... which the victim was walking out of a convenience store and witnessed an ... to his vehicle, striking his vehicle and leaving the ...
(Date:2/2/2016)... , Feb. 2, 2016 Checkpoint ... that Rising Market Are you interested in ... forecasts revenues for checkpoint inhibitors. Visiongain,s report gives ... submarket, product and national level. Avoid falling ... what progress, opportunities and revenues those emerging cancer ...
(Date:2/1/2016)... February 1, 2016 Rising sales ... drive global touchfree intuitive gesture control market ... Rising sales of consumer electronics coupled with new technological ... size through 2020   ... with new technological advancements to drive global touchfree intuitive ...
Breaking Biology News(10 mins):